Efficacy and toxicity of Eudragit-coated chitosan-succinyl-prednisolone conjugate microspheres using rats with 2,4,6-trinitrobenzenesulfonic acid-induced colitis

International Journal of Pharmaceutics

Volumn 358, Issue 1-2, 2008, Pages 296-302

  Onishi, Hiraku ^a   Oosegi, Tomoko ^a   Machida, Yoshiharu ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

2,4,6 Trinitrobenzenesulfonic acid induced colitis; Efficacy; Eudragit L100 coated chitosan succinyl prednisolone conjugate microspheres; Toxicity

Indexed keywords

CHITOSAN; EUDRAGIT; MICROSPHERE; MYELOPEROXIDASE; PREDNISOLONE; PREDNISOLONE SODIUM SUCCINATE; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; COLITIS; COLON; CONTROLLED STUDY; DISEASE SEVERITY; DRUG COATING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; ENZYME ACTIVITY; IN VIVO STUDY; INFLAMMATION; MALE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; RAT; THYMUS ATROPHY; TOXICITY TESTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BODY WEIGHT; CHITOSAN; COLITIS; DRUG DELIVERY SYSTEMS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; MALE; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; ORGAN SIZE; PARTICLE SIZE; POLYMETHACRYLIC ACIDS; PREDNISOLONE; RATS; RATS, WISTAR; TISSUE DISTRIBUTION; TRINITROBENZENESULFONIC ACID;

EID: 44449149169     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.02.015     Document Type: Article

References (16)

1. Ardizzone S., and Bianchi Porro G. A practical guide to the management of distal ulcerative colitis. Drugs 55 (1998) 519-542
2. Azab A.K., Orkin B., Doviner V., Nissan A., Klein M., Srebnik M., and Rubinstein A. Crosslinked chitosan implants as potential degradable devices for brachytherapy: in vitro and in vivo analysis. J. Control. Release 111 (2006) 281-289
3. Campieri M., Ferguson A., Doe W., Persson T., and Nilsson L.G. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 41 (1997) 209-214
4. Danese S., and Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J. Gastroenterol. 12 (2006) 4807-4812
5. Fiocchi C. Inflammatory bowel disease. Current concepts of pathogenesis and implications for therapy. Minerva Gastroenterol. Dietol. 48 (2002) 215-226
6. Kesisoglou F., and Zimmermann E.M. Novel drug delivery strategies for the treatment of inflammatory bowel disease. Expert Opin. Drug Deliv. 2 (2005) 451-463
7. Lamprecht A., Schafer U., and Lehr C.M. Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm. Res. 18 (2001) 788-793
8. Lamprecht A., Ubrich N., Yamamoto H., Schafer U., Takeuchi H., Maincent P., Kawashima Y., and Lehr C.M. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 299 (2001) 775-781
9. Onishi H., Oosegi T., Machida Y., and McGinity J.W. Preparation and in vitro evaluation of chitosan microspheres containing prednisolone: comparison of simple and conjugate microspheres. Drug Dev. Ind. Pharm. 31 (2005) 597-605
10. Onishi H., Oosegi T., Machida Y., and McGinity J.W. Eudragit coating of chitosan-prednisolone conjugate microspheres and in vitro evaluation of coated microspheres. Drug Dev. Ind. Pharm. 33 (2007) 848-854
11. Oosegi T., Onishi H., and Machida Y. Novel preparation of enteric-coated chitosan-prednisolone conjugate microspheres and in vitro evaluation of their potential as a colonic delivery system. Eur. J. Pharm. Biopharm. 68 (2008) 260-267
12. Oosegi T., Onishi H., and Machida Y. Gastrointestinal distribution and absorption behavior of Eudragit-coated chitosan-prednisolone conjugate microspheres in rats with TNBS-induced colitis. Int. J. Pharm. 348 (2008) 80-88
13. Tozaki H., Fujita T., Odoriba T., Terabe A., Okabe S., Muranishi S., and Yamamoto A. Validation of a pharmacokinetic model of colon-specific drug delivery and the therapeutic effects of chitosan capsules containing 5-aminosalicylic acid on 2,4,6-trinitrobenzenesulphonic acid-induced colitis in rats. J. Pharm. Pharmacol. 51 (1999) 1107-1112
14. Tozaki H., Odoriba T., Okada N., Fujita T., Terabe A., Suzuki T., Okabe S., Muranishi S., and Yamamoto A. Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. J. Control. Release 82 (2002) 51-61
15. Watts P.J., Barrow L., Steed K.P., Wilson C.G., Spiller R.C., Melia C.D., and Davies M.C. The transit rate of different-sized model dosage forms through the human colon and the effects of a lactulose-induced catharsis. Int. J. Pharm. 87 (1992) 215-221
16. Yano H., Hirayama F., Kamada M., Arima H., and Uekama K. Colon-specific delivery of prednisolone-appended alpha-cyclodextrin conjugate: alleviation of systemic side effect after oral administration. J. Control. Release 79 (2002) 103-112